Nasal olanzapine formulations and methods of use thereof
JP2025510082A5Pending Publication Date: 2026-03-31NEURELIS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024556339
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2026-03-31
AI Technical Summary
Technical Problem
Existing olanzapine injections require re-formulation and injection by medical professionals, which poses problems with high invasiveness, high pain, and potential risk of needle stab damage to caregivers and patients.
Method used
A non-aqueous-based solution is developed containing 1% to 15% orylazole or a suitable salt thereof, 0.1% to 1% dodecanol methoraxetate, 30% to 40% N,N-dimethylformamide and 40% to 70% polyethylene glycol for nasal administration.
Benefits of technology
Achieve rapid and efficient administration without re-formulation and medical professional participation, reducing invasiveness and pain, and improving safety and convenience.
✦ Generated by Eureka AI based on patent content.
Abstract
A composition for nasal administration of olanzapine and methods of using the same for treating various symptoms of schizophrenia, schizoaffective disorder and bipolar disorder, such as acute agitation, mania and mixed episodes. The nasal olanzapine composition contains dodecylmaltoside to improve the bioavailability of olanzapine and is administered via the nasal mucosa to avoid direct systemic administration.
Need to check novelty before this filing date? Find Prior Art